UNIVERSITY OF CALIFORNIA-IRVINE
Targeting p38/JNK MAPK to ameliorate cisplatin-induced adverse sequelae on the nervous system
Targeting p38/JNK MAPK to ameliorate cisplatin-induced adverse sequelae on the nervous system is a funding opportunity from UNIVERSITY OF CALIFORNIA-IRVINE, up to 82514, closing June 30, 2027.
Jun 30, 2027
(334d left)Overview
Chemotherapy-related cognitive impairment (CRCI, chemobrain), chemotherapy-induced peripheral neuropathy (CIPN) and gait changes are debilitating side-effects of cancer treatment with platinum agents (e.g., cisplatin), taxanes, and vinca alkaloids. Cisplatin is widely used as a chemotherapeutic agent to treat ovarian…